FOV2302 (Ecallantide)

Phase 1Peptide

FOV2302 (Ecallantide) is one of 36 small molecule programs targeting Retinal Vein Occlusion. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal Vein OcclusionActive, not recruiting

Retinal Vein OcclusionPhase 1

Active, not recruiting

Competition

Competitive Landscape

58 competitors in Retinal Vein Occlusion

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

6 2

Niacor

Ozurdex

4 4

Intravitreal Aflibercept

Regeneron

Approved

2 5

Mecobalamin

Eisai

Approved

1 6

Celestone

Lucentis

1 8

Vabysmo

Roche

Phase 3

2 9

Beovu

Novartis

Phase 3

2 10

Avastin

BBio-Thera Solutions

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinal Vein Occlusion1 trial

Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion

Terminated·FFovea Pharmaceuticals SA·Phase 1·NCT00969293·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FOV2302 (Ecallantide). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOV2302 (Ecallantide) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOV2302 (Ecallantide). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fovea Pharmaceuticals SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 1[1]
Company: FFovea Pharmaceuticals SA

FOV2302 (Ecallantide)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Retinal Vein Occlusion1 trial

References

Drug Info

Quick Facts

Related News